Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta

Taiwanese Journal of Obstetrics and Gynecology

Volumn 45, Issue 2, 2006, Pages 100-106

  Tseng, Jenn Jhy ^a,b,c   Chou, Min Min ^a,b,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Growth; Invasion; Placenta accreta; Trophoblast

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MATRIX METALLOPROTEINASE; ONCOPROTEIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BLEEDING; CESAREAN SECTION; GROWTH; HUMAN; MATERNAL CARE; MATERNAL MORTALITY; PLACENTA ACCRETA; PLACENTA VILLUS; PROTEIN EXPRESSION; REVIEW; TROPHOBLAST;

EID: 33745918644     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(09)60205-9     Document Type: Review

References (81)

1. Chou MM, Ho ES, Lee YH. Prenatal diagnosis of placenta previa accreta by transabdominal color Doppler ultrasound. Ultrasound Obstet Gynecol 2000;15:28-35.
2. Earl U, Bulmer JN, Briones A. Placenta accreta: an immunohistological study of trophoblast populations. Placenta 1987;8:273-82.
3. Hochner-Celnikier D, Prus D, Matanes M, Yisraeli J, Yagel S, Goldman-Wohl D. Pathogenesis of placenta accreta is not related to over-invasiveness of the trophoblast. Am J Obstet Gynecol 2004;191(Suppl 1):S88.
4. Ohlsson R. Growth factors, protooncogenes and human placental development. Cell Differ Dev 1989;28:1-15.
5. Mühlhauser J, Crescimanno C, Kaufmann P, Höfler H, Zaccheo D, Castellucci M. Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGF-R. J Histochem Cytochem 1993;41:165-73 .
6. Simon C, Frances A, Piguette GN, el Danasouri I, Zurawski G, Dang W, Polan ML. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. Endocrinology 1994;134:521-8.
7. Graham CH, Lala PK. Mechanism of control of trophoblast invasion in situ. J Cell Physiol 1991;148:228-34.
8. Aplin JD, Lacey H, Haigh T, Jones CJP, Chen CP, Westwood M. Growth factor-extracellular matrix synergy in the control of trophoblast invasion. Biochem Soc Trans 2000;28:199-202.
9. Karmakar S, Das C. Regulation of trophoblast invasion by IL-1β and TGF-β1. Am J Reprod Immunol 2002;48:210-19.
10. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648-55.
11. Bjercke S. Normal implantation is important in order to avoid pregnancy complications and diseases later in life. Tidsskr Nor Laegeforen 1999;119:3903-8.
12. Genbacev O, Joslin P, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invertebr 1996;97:540-50.
13. Strickland S, Richards WG. Invasion of the trophoblasts. Cell 1992;71:355-7.
14. Fisher SJ, Zhou Y, Huang L, Winn VD. When is seeing believing? The use of color Doppler ultrasound to diagnose placenta accreta in the first trimester of pregnancy. Ultrasound Obstet Gynecol 2002;19:540-2.
15. Gallery ED, Campbell S, Ilkovski B, Sinosich MJ, Jackson C. A novel in vitro co-culture system for the study of maternal decidual endothelial cell-trophoblast interactions in human pregnancy. Br J Obstet Gynaecol 2001;108:651-3.
16. Tseng JJ, Hsu SL, Wen MC, Ho ES, Chou MM. Expression of epidermal growth factor receptor and c-erbB-2 oncoprotein in trophoblast populations of placenta accreta. Am J Obstet Gynecol 2004;191:2106-13.
17. Vuorela P, Hatva E, Lymboussaki A, et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997;56:489-94.
18. Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 1995;12:235-43.
19. Khaliq A, Li XF, Shams M, et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996;13:243-50.
20. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998;159:459-67.
21. Kumazaki K, Nakayama M, Suehara N, Wada Y. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathological conditions. Hum Pathol 2002;33:1069-77.
22. de Vries C, Escobedo J, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
23. Terman BI, Dougher-Vermazen M, Carrion M, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992;187:1579-86.
24. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
25. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is the ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290-8.
26. Enholm B, Jussila L, Karkkainen M, Alitano K. Vascular endothelial growth factor C: a growth factor for lymphatic and blood vascular endothelial cells. Trends Cardiovasc Med 1998;8:292-7.
27. Talamentes A, Ogren L. The placenta as an endocrine organ: polypeptides. In: Knobil E, Neill J, eds. The Physiology of Reproduction. New York: Raven Press, 1988:2093-144.
28. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol 2004;190:1541-50.
29. Ebos JM, Bocci G, Man S, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004;2:315-26.
30. Vuorela P, Carpén O, Tulppala M, Halmesmäki E. VEGF, its receptors and the Tie receptors in recurrent miscarriage. Mol Hum Reprod 2000;6:276-82.
31. Helske S, Vuorela P, Carpén O, Hornig C, Weich H, Halmesmäki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-10.
32. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000;80:443-54.
33. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006;27:70-8.
34. Dunk C, Ahmed A. Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast. Histol Histopathol 2001;16:359-75.
35. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003;28:488-94.
36. Islami D, Mock P, Bischof P. Effects of human chorionic gonadotropin on trophoblast invasion. Semin Reprod Med 2001;19:49-53.
37. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002;87:5290-6.
38. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/ growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219-38.
39. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
40. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-8.
41. Kuo B, Li Y, Zhang L, et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol 2004;76:129-37.
42. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24:586-603.
43. Partanen J, Dumont D. Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. In: Claesson-Welsh L, ed. Vascular Growth Factors and Angiogenesis. Berlin: Springer-Verlag, 1999:159-72.
44. Lin WC, Li AF, Chi CW, Chung WW, Huang CL, Lui WY. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res 1999;5:1745-51.
45. Currie MJ, Gunningham SP, Han C, Scott PA, Robinson BA, Harris AL. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin Cancer Res 2001;7:918-27.
46. Wulff C, Wilson H, Dickson SE, Wiegand SJ, Fraser HM. Hemochorial placentation in the primate: expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod 2002;66:802-12.
47. Regnault TR, Galan HL, Parker TA, Anthony RV. Placental development in normal and compromised pregnancies-a review. Placenta 2002;23(Suppl A):S119-29.
48. Torry DS, Ahn H, Barnes EL, Torry RJ. Placenta growth factor: potential role in pregnancy. Am J Reprod Immunol 1999;41:79-85.
49. Wulff C, Weigand M, Kreienberg R, Fraser HM. Angiogenesis during primate placentation in health and disease. Reproduction 2003;126:569-77.
50. Tseng JJ, Hsu SL, Ho ES, Hsieh YT, Wen MC, Chou MM. Differential expression of angiopoietin-1, angiopoietin-2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol 2006;194:564-71.
51. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol 2000;156:2185-99.
52. Rowe AJ, Wulff C, Fraser HM. Localization of mRNA for vascular endothelial growth factor (VEGF), angiopoietins and their receptors during the periimplantation period and early pregnancy in marmosets (Callithrix jacchus). Reproduction 2003;126:227-38.
53. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie-2. Cardiovasc Res 2001;49:659-70.
54. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-40.
55. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor Tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004;43:423-8.
56. Matsunaga T, Warltier DC, Tessmer J, Weihrauch D, Simons M, Chilian WM. Expression of VEGF, angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 2003;285:H352-8.
57. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D. Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol 2005;11:964-9.
58. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kawaga S. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 2005;95:660-3.
59. Oliner J, Min H, Leal J, Yu D, Rao S, You E. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16.
60. Durkin AJ, Bloomston M, Yeatman TJ, Gilbert-Barness E, Cojita D, Rosemurgy AS. Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg 2004;199:724-31.
61. Hurskainen T, Seiki M, Apte SS, Syrjäkallio-Ylitalo M, Sorsa T, Oikarinen A, Autio-Harmainen H. Production of membrane-type matrix metalloproteinase-1 (MT-MMP-1) in early human placenta: a possible role in placental implantation? J Histochem Cytochem 1998;46:221-9.
62. Huppertz B, Kerschanska S, Demir AY, Frank HG, Kaufmann P. Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res 1998;291:133-48.
63. Librach CL, Werb Z, Fitzgerald ML, et al. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol 1991;113:437-49.
64. Hanemaaijer R, Koolwijk P, Clercq LL, de Vree WJA, van Hinsbergh VWM. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Biochem J 1993;296:803-9.
65. Sato H, Takino T, Okada Y. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-5.
66. Leber T, Boyd R, Balkwill F. Tumour cell-stromal cell interactions: proteases and protease inhibitors. In: Sharp F, Blackett T, Berek J, Bast R, eds. Ovarian Cancer 5. Oxford: Isis Medical Media Ltd, 1998:121-9.
67. Aplin JD. Implantation, trophoblast differentiation and haemochorial placentation: mechanistic evidence in vivo and in vitro. J Cell Sci 1991;99:681-92.
68. Morgan M, Kniss D, McDonnell S. Expression of metalloproteinases and their inhibitors in human trophoblast continuous cell lines. Exp Cell Res 1998;242:18-26.
69. Bjorn SF, Hastrup N, Lund LR, Dano K, Larsen JF, Pyke C. Coordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation. Mol Hum Reprod 1997;3:713-23.
70. Bjorn SF, Hastrup N, Larsen JL, Lund LR, Pyke C. Messenger RNA for membrane type 2 matrix metalloproteinases MT2-MMP is expressed in human placenta of first trimester. Placenta 2000;21:170-6.
71. Cao J, Sato H, Takino T, Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995;270:801-5.
72. Nawrocki B, Polette M, Marchand V, et al. Membrane-type matrix metalloproteinase-1 expression at the site of human placentation. Placenta 1996;17:565-72.
73. Denhardt DT, Feng B, Edwards DR. Tissue inhibitor of metalloproteinases: structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-41.
74. Murray GI, Duncan ME, Arbucle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.
75. Polette M, Nawrocki B, Pintiaux A, et al. Expression of gelatinases A and B and their tissue inhibitors by cells of early and term placenta and gestational endometrium. Lab Invest 1994;71:838-46.
76. Ruck P, Marzusch K, Horny HP, Dietl J, Kaiserling E. Distribution of tissue inhibitor of metalloproteinases-2 (TIMP-2) in trophoblasts of early human pregnancy. Placenta 1995;16:A62.
77. Ruck P, Marzusch K, Horny HP, Dietl J, Kaiserling E. The distribution of tissue inhibitor of metalloproteinases-2 (TIMP-2) in the human placenta. Placenta 1996;17:263-6.
78. Van Meter TE, Broaddus WC, Rooprai HK, Pilkington GJ, Fillmore HL. Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas. Neuro-oncol 2004;6:188-99.
79. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003;106:848-55.
80. Sounni NE, Roghi C, Chabottaux V, et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004;279:13564-74.
81. Guo P, Imanishi Y, Cackowski FC, et al. Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 2005;166:877-90.